Skip to main content
. 2016 Apr;68(2):264–355. doi: 10.1124/pr.115.011478

TABLE 1.

A comparison of human doses of selected hallucinogens with their potency using drug discrimination tests in LSD-trained rats

Where available, Ki values for cloned human 5-HT2A and 5-HT2C receptors are also listed for comparison. Compounds are ranked by relative human potency. Reproduced by permission of Elsevier from Nichols (2004).

Druga Ki for5-HT2Ab Ki for5-HT2Cb DD ED50c Potency Relative to LSD
(Rat DD) Human Dosed Potency Relative to LSD (Human)
nM μM/kg mg
EthLAD 0.02 185 0.04–0.15 140
AllyLAD 0.013 285 0.08–0.16 110
LSD 2–4 3–6 0.037 100 0.06–0.20 100
ProLAD 0.037 100 0.10–0.20 90
DOB 0.6 1.3 1.06 2.3 1–3 7
DOI 0.7 2.4 0.28 9.2 1.5–3 6
DOM 19 ND 0.89 3.3 3–10 2
Psilocin 15–25 10 1.0 2.6 10–15 1
DMCPA ND ND 0.66 4.5 15–20 0.7
MEM 73 124 12 0.2 20–50 0.4
MMDA-2 ND ND 7 0.4 25–50 0.4
Mescaline 550 300 34 0.08 200–400 0.04

AllyLAD, N-allyl-N(6)-norLSD; DD, drug discrimination; DMCPA, (±)-trans-2,5-dimethoxy-4-methylphenylcyclopropylamine; EthLAD, N-ethyl-N(6)-norLSD; MEM, (±)-2,5-dimethoxy-4-ethoxyamphetamine; MMDA-2, (±)-2-methoxy-4,5-methylenedioxyamphetamine; ProLAD, N-n-propyl-N(6)-norLSD.

a

Drug abbreviations are from Shulgin and Shulgin (1991, 1997).

b

Affinity of phenethylamines in cloned receptors taken from Nelson et al. (1999); mescaline affinity is from Monte et al. (1997).

dAveraged dose range from Shulgin & Shulgin (1991, 1997) (LSD = 100).